Modulating Glycogen Synthase Kinase-3 in Chronic Lymphocytic Leukemia

Simple item page
dc.contributor.authorLang, Rebecca
dc.date.accessioned2015-06-01T19:24:46Z
dc.date.available2015-06-01T19:24:46Z
dc.date.issued2015-07-31
dc.description.abstractChronic lymphocytic leukemia (CLL) is the most common hematological malignancy in North America and Europe with a median age of onset of 72. Due to the advanced age of most patients with CLL, many are unable to tolerate standard treatments and receive sub-optimal care. Despite the availability of various treatment options, CLL remains incurable. Glycogen synthase kinase-3 (GSK-3) is a metabolic enzyme dysregulated in CLL. It has two isoforms: GSK-3α and β. Our hypothesis is that GSK-3 is a critical enzyme for CLL cell survival and therefore a target that can be exploited for therapeutic benefit. In this study the effect of chemical pan-inhibition of GSK-3 is characterized using lithium chloride and SB216763 (SB) in CLL- like cell lines. Pan inhibition with LiCl and SB causes a decrease in cell viability after 48 and 72 hours of treatment with β-catenin stabilization. Secondly, isoform-specific loss of GSK- 3α and β by RNA interference is confirmed in CLL-like cell lines. Loss of either isoform alone did not result in β-catenin stabilization. Finally, phenotypic effects of novel pan- and isoformselective GSK-3 inhibitors are characterized in primary CLL cells. The Broad Institute of MIT and Harvard supplied five novel inhibitory compounds including two pan inhibitors, one GSK-3β inhibitor and two GSK-3α inhibitors. Only the pan- and GSK-3β inhibitors reduced viability in a dose- and time-dependent manner. However, β-catenin stabilization was also dose-dependent. These findings question isoform selectivity of the novel compounds tested and suggest that further studies are required to fully characterize their on and off target effects.en_US
dc.identifier.urihttp://hdl.handle.net/1993/30546
dc.language.isoengen_US
dc.rightsopen accessen_US
dc.subjectglycogen synthase kinase-3en_US
dc.subjectchronic lymphocytic leukemiaen_US
dc.titleModulating Glycogen Synthase Kinase-3 in Chronic Lymphocytic Leukemiaen_US
dc.typeOtheren_US
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.17 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
College of Medicine - B.Sc. (Med) Projects